GlassScriptPhysician profile
Sheena Eslinger
NPI 1942675673
$13,435.87
in general payments reported to CMS, 2019-2025
33 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,295 · 2022: $1,864 · 2023: $2,479 · 2024: $3,177 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,221 · Education: $56.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,220.60 |
| Education | $56.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,817.71 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,881.12 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,320.46 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $944.04 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $643.42 | 2021-2025 | |
| Genzyme Corporation | $578.03 | 2022-2025 | |
| Qol Medical, LLC | $515.82 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $490.44 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $421.42 | 2021-2025 | Epclusa, Livdelzi |
| Ironwood Pharmaceuticals, INC | $371.94 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $364.72 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $364.30 | 2024-2025 | Omvoh |
| Celgene Corporation | $279.39 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $198.06 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $180.21 | 2021-2024 | Ocaliva |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $151.60 | 2021-2023 | |
| Redhill Biopharma INC. | $118.74 | 2021-2023 | |
| Madrigal Pharmaceuticals | $117.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $103.85 | 2022-2023 | Avsola, Amjevita |
| Abiomed | $95.47 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $64.11 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $56.86 | 2022 | |
| Braintree Laboratories, INC. | $51.82 | 2021-2025 | Suflave |
| Aimmune Therapeutics, INC. | $47.30 | 2024 | |
| Celltrion USA INC. | $45.96 | 2023-2024 | Yuflyma, Zymfentra |
| Daiichi Sankyo INC. | $41.68 | 2022 | |
| Mallinckrodt Hospital Products INC. | $36.23 | 2023 | Terlivaz |
| Fresenius Kabi USA, LLC | $31.44 | 2023 | Idacio |
| Organon LLC | $30.84 | 2023 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $24.48 | 2025 | Iqirvo |
| Novo Nordisk INC | $20.50 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2024 | Cyltezo |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Eslinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.